Bonferroni test. Bio metrika 1988;75:383 –386 9. Dmitrienko A, Molenberghs G, Chuang- Stein C, Offen W. Analysis of Clinical Trials Using SAS: A Practical Guide .C a r y ,N C , SAS Institute Inc, 2005 10. Bergenstal RM, Wysham C, Macconell L, et al. Ef ﬁcacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomisedtrial. Lancet 2010;376:431 –439 11. Tan MH, Johns D, Strand J, et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid pro ﬁles in patients with type 2 di- abetes. Diabet Med 2004;21:859 –866 12. Tan MH, Baksi A, Krahulec B, et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. DiabetesCare 2005;28:544 –550 13. Rosenstock J, Kim SW, Baron MA, et al. Efﬁcacy and tolerability of initial com- bination therapy with vildagliptin and